Wall Street Zen Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts have also recently weighed in on the company. Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Jefferies Financial Group raised their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. UBS Group lifted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Finally, Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $779.45.

Regeneron Pharmaceuticals Trading Up 2.6%

Shares of REGN stock opened at $767.96 on Friday. The company has a market capitalization of $80.71 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.21 and a beta of 0.37. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $790.98. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $682.40 and a 200 day moving average price of $601.23.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the prior year, the firm earned $12.46 earnings per share. The company’s quarterly revenue was up .9% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. PGGM Investments lifted its position in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after acquiring an additional 51,900 shares during the period. Founders Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after purchasing an additional 538 shares in the last quarter. Sepio Capital LP lifted its position in Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after purchasing an additional 842 shares during the period. Generate Investment Management Ltd bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $6,300,000. Finally, Hudson Value Partners LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $398,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.